Zoetis Inc. discovers, develops, manufactures, and markets veterinary vaccines and medicines in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company offers anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; and parasiticides that prevent or eliminate external and internal parasites that include fleas, ticks, and worms. It also provides medicated feed additives that offer medicines to livestock; and other pharmaceutical products, which comprise allergy and dermatology, pain and sedation, antiemetic, reproductive, and oncology products. In addition, the company offers other product categories, including nutritionals and agribusiness services, as well as products and services in complementary areas, such as biodevices, diagnostics, and genetics. It markets its products to veterinarians, livestock producers, and people who raise and care for farm and companion animals through its sales representatives, and technical and veterinary operations specialists. The company was founded in 1952 and is headquartered in Parsippany, New Jersey.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Phone973-822-7000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$5.83 billion
Profitability
Miscellaneous
Employees9,200
Next Earnings Date5/1/2019 (Estimated)
OptionableOptionable
Zoetis (NYSE:ZTS) Frequently Asked Questions
What is Zoetis' stock symbol?
Zoetis trades on the New York Stock Exchange (NYSE) under the ticker symbol "ZTS."
How often does Zoetis pay dividends? What is the dividend yield for Zoetis?
Zoetis declared a quarterly dividend on Wednesday, February 13th. Investors of record on Thursday, April 18th will be given a dividend of $0.164 per share on Monday, June 3rd. This represents a $0.66 annualized dividend and a yield of 0.70%. The ex-dividend date of this dividend is Wednesday, April 17th. View Zoetis' Dividend History.
How will Zoetis' stock buyback program work?
Zoetis declared that its Board of Directors has approved a stock buyback program on Wednesday, December 12th 2018, which authorizes the company to buyback $2,000,000,000.00 in shares, according to EventVestor. This buyback authorization authorizes the company to reacquire up to 4.7% of its shares through open market purchases. Shares buyback programs are generally a sign that the company's board believes its shares are undervalued.
How were Zoetis' earnings last quarter?
Zoetis Inc (NYSE:ZTS) posted its quarterly earnings results on Thursday, February, 14th. The company reported $0.79 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $0.77 by $0.02. The firm had revenue of $1.56 billion for the quarter, compared to the consensus estimate of $1.53 billion. Zoetis had a return on equity of 73.85% and a net margin of 24.51%. The company's revenue for the quarter was up 7.1% on a year-over-year basis. During the same quarter last year, the business posted $0.69 EPS. View Zoetis' Earnings History.
When is Zoetis' next earnings date?
What guidance has Zoetis issued on next quarter's earnings?
Zoetis updated its FY19 earnings guidance on Thursday, February, 14th. The company provided EPS guidance of $3.42-3.52 for the period, compared to the Thomson Reuters consensus estimate of $3.44. The company issued revenue guidance of $6.175-6.30 billion, compared to the consensus revenue estimate of $6.22 billion.Zoetis also updated its FY 2019 guidance to $3.42-3.52 EPS.
What price target have analysts set for ZTS?
13 analysts have issued 1 year price objectives for Zoetis' shares. Their forecasts range from $86.00 to $105.00. On average, they anticipate Zoetis' stock price to reach $96.8333 in the next year. This suggests a possible upside of 3.6% from the stock's current price. View Analyst Price Targets for Zoetis.
What is the consensus analysts' recommendation for Zoetis?
13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zoetis in the last year. There are currently 5 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Zoetis.
What are Wall Street analysts saying about Zoetis stock?
Here are some recent quotes from research analysts about Zoetis stock:
- 1. According to Zacks Investment Research, "Zoetis continues to maintain momentum on the back of growth from new parasiticide products (Simparica and Stronghold Plus), vaccines, strong dermatology portfolio and the addition of the Abaxis diagnostics portfolio. The company’s companion animal business has been performing well. The Abaxis acquisition has strengthed the company’s presence in the animal health diagnostics market, a fast-growing portion of the animal health industry which should further boost sales. However, disease outbreak among animals is a material cause of concern for Zoetis’ livestock products. Such outbreaks may hurt regional or global sales of particular animal-derived food products or result in reduced exports of the same, due to either heightened export restrictions or import prohibitions, in turn, dampening demand for livestock products. Shares of Zoetis have outperformed the industry in the past year. Estimates are stable ahead of the Q4 results." (2/16/2019)
- 2. Cantor Fitzgerald analysts commented, ". We reiterate our Overweight rating and raise our 12-month PT for ZTS shares to $105 from $98. The increase in our PT is driven by multiple expansion. Given the company’s durable business model and the positive outlook for macro factors, we think ZTS’s multiple will hold and upwards earnings revisions should drive shares higher. We think ZTS’s multiple will be supported by: 1) its durable business model, 2) positive outlook for macro factors, and 3) solid execution by management. Upwards earnings revisions could come from: 1) higher-than- anticipated peak sales for new launches, 2) better-than-expected operating margins in 2018+, and 3) M&A." (10/17/2018)
Has Zoetis been receiving favorable news coverage?
News coverage about ZTS stock has been trending very negative on Friday, according to InfoTrie. The research firm scores the sentiment of news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Zoetis earned a media sentiment score of -3.0 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 6.0 out of 10, indicating that recent news coverage is somewhat likely to have an effect on the stock's share price in the next few days.
Who are some of Zoetis' key competitors?
Some companies that are related to Zoetis include Abbott Laboratories (ABT), Eli Lilly And Co (LLY), Novo Nordisk A/S (NVO), AbbVie (ABBV), Sanofi (SNY), AstraZeneca (AZN), GlaxoSmithKline (GSK), Bristol-Myers Squibb (BMY), Bayer (BAYRY), Celgene (CELG), Shire (SHPG), Vertex Pharmaceuticals (VRTX), Allergan (AGN), Regeneron Pharmaceuticals (REGN) and Takeda Pharmaceutical (TKPYY).
What other stocks do shareholders of Zoetis own?
Who are Zoetis' key executives?
Zoetis' management team includes the folowing people:
- Mr. Juan Ramón Alaix, CEO & Director (Age 68)
- Mr. Glenn C. David, Exec. VP & CFO (Age 47)
- Dr. Catherine A. Knupp, Exec. VP and Pres of R&D (Age 58)
- Mr. Clinton A. Lewis Jr., EVP and Grp Pres of Intl. Ops., Comm. Devp., Glbl Genetics, Aquatic Health & Human Medical Digs (Age 52)
- Ms. Kristin C. Peck, Exec. VP and Group Pres of U.S. Operations, Bus. Devel. & Strategy (Age 48)
Who are Zoetis' major shareholders?
Zoetis' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.64%), Oregon Public Employees Retirement Fund (2.98%), Polen Capital Management LLC (1.99%), Massachusetts Financial Services Co. MA (1.60%), Geode Capital Management LLC (1.30%) and Brown Advisory Inc. (1.27%). Company insiders that own Zoetis stock include Catherine A Knupp, Clinton A Jr Lewis, Glenn David, Heidi C Chen, Juan Ramon Alaix, Khosla Sanjay, Kristin C Peck, Roman Trawicki, Roxanne Lagano and Willie M Reed. View Institutional Ownership Trends for Zoetis.
Which institutional investors are selling Zoetis stock?
ZTS stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Prudential Financial Inc., BlackRock Inc., Aviva PLC, State Treasurer State of Michigan, Bessemer Group Inc., DSM Capital Partners LLC and Canada Pension Plan Investment Board. Company insiders that have sold Zoetis company stock in the last year include Catherine A Knupp, Clinton A Jr Lewis, Glenn David, Heidi C Chen, Juan Ramon Alaix, Khosla Sanjay, Kristin C Peck, Roman Trawicki, Roxanne Lagano and Willie M Reed. View Insider Buying and Selling for Zoetis.
Which institutional investors are buying Zoetis stock?
ZTS stock was purchased by a variety of institutional investors in the last quarter, including Oregon Public Employees Retirement Fund, Two Sigma Advisers LP, CIBC Private Wealth Group LLC, Mackenzie Financial Corp, Geode Capital Management LLC, Assenagon Asset Management S.A., California Public Employees Retirement System and Eagle Asset Management Inc.. View Insider Buying and Selling for Zoetis.
How do I buy shares of Zoetis?
Shares of ZTS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Zoetis' stock price today?
One share of ZTS stock can currently be purchased for approximately $93.47.
How big of a company is Zoetis?
Zoetis has a market capitalization of $44.75 billion and generates $5.83 billion in revenue each year. The company earns $1.43 billion in net income (profit) each year or $3.13 on an earnings per share basis. Zoetis employs 9,200 workers across the globe.
What is Zoetis' official website?
How can I contact Zoetis?
Zoetis' mailing address is 10 Sylvan Way, Parsippany NJ, 07054. The company can be reached via phone at 973-822-7000 or via email at [email protected]
MarketBeat Community Rating for Zoetis (NYSE ZTS)
MarketBeat's community ratings are surveys of what our community members think about Zoetis and other stocks. Vote "Outperform" if you believe ZTS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ZTS will underperform the S&P 500 over the long term. You may vote once every thirty days.
